APA (7th ed.) Citation

Wu, M., Li, Q., Fang, M., Zhang, H., & Ding, Y. Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis. BMC.

Chicago Style (17th ed.) Citation

Wu, Min, Qianqian Li, Min Fang, Hong Zhang, and Yanhua Ding. Safety, Pharmacokinetics, Preliminary Efficacy, Pharmacodynamics, and Immunogenicity of QX002N, an Anti-IL-17A Monoclonal Antibody, After Short-term Treatment of Active Ankylosing Spondylitis. BMC.

MLA (9th ed.) Citation

Wu, Min, et al. Safety, Pharmacokinetics, Preliminary Efficacy, Pharmacodynamics, and Immunogenicity of QX002N, an Anti-IL-17A Monoclonal Antibody, After Short-term Treatment of Active Ankylosing Spondylitis. BMC.